Business Description
Corvus Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US2210151005
Description
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 67.49 | |||||
Equity-to-Asset | 0.79 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.03 | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 30.8 | |||||
3-Year EPS without NRI Growth Rate | -40.9 | |||||
3-Year FCF Growth Rate | 25 | |||||
3-Year Book Growth Rate | -32.3 |
Momentum Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 50.89 | |||||
9-Day RSI | 55.07 | |||||
14-Day RSI | 58.49 | |||||
6-1 Month Momentum % | 133.72 | |||||
12-1 Month Momentum % | 174.05 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 3.62 | |||||
Quick Ratio | 3.62 | |||||
Cash Ratio | 3.54 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -20 | |||||
Shareholder Yield % | 0.35 |
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -52.1 | |||||
ROA % | -43.46 | |||||
ROIC % | -108.79 | |||||
3-Year ROIIC % | -85.6 | |||||
ROC (Joel Greenblatt) % | -1694.35 | |||||
ROCE % | -53.64 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 6.86 | |||||
Price-to-Tangible-Book | 6.84 | |||||
EV-to-EBIT | -13.04 | |||||
EV-to-EBITDA | -13.1 | |||||
EV-to-FCF | -14.37 | |||||
Price-to-Net-Current-Asset-Value | 9.97 | |||||
Price-to-Net-Cash | 10.42 | |||||
Earnings Yield (Greenblatt) % | -7.67 | |||||
FCF Yield % | -6.04 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Corvus Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -0.406 | ||
Beta | -1 | ||
Volatility % | 103 | ||
14-Day RSI | 58.49 | ||
14-Day ATR (€) | 0.21046 | ||
20-Day SMA (€) | 4.519 | ||
12-1 Month Momentum % | 174.05 | ||
52-Week Range (€) | 0.99 - 5.22 | ||
Shares Outstanding (Mil) | 62.55 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Corvus Pharmaceuticals Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Corvus Pharmaceuticals Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Corvus Pharmaceuticals Inc Frequently Asked Questions
What is Corvus Pharmaceuticals Inc(STU:C17)'s stock price today?
When is next earnings date of Corvus Pharmaceuticals Inc(STU:C17)?
Does Corvus Pharmaceuticals Inc(STU:C17) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |